Author:
Marrone Kristen A.,Brahmer Julie R.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference53 articles.
1. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
2. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012
3. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer;Topalian;N Engl J Med,2012
4. Talactoferrin alfa versus placebo in patients with refractory advanced non–small-cell lung cancer (FORTIS-M trial);Ramalingam;Ann Oncol,2013
5. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non–small-cell lung cancer;Jansen;J Immunother,1992
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献